Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
Oscar Lindblad(Skåne University Hospital), Julhash U. Kazi(University of Barisal)
Cited by 130
Related Papers
BEX1 acts as a tumor suppressor in acute myeloid leukemia
|Oncotarget|2015|27
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
|International Journal of Molecular Sciences|2023|14
Advancing Precision Oncology Using Data-Driven Machine Learning Approaches
|Cancer Biome and Targeted Therapy|2026|0